Skip to content

A prospective study of multimodal imaging to evaluate the efficacy of neoadjuvant chemotherapy for breast cancer

A prospective study of multimodal imaging to evaluate the efficacy of neoadjuvant chemotherapy for breast cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035381
Enrollment
Unknown
Registered
2020-08-09
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Gold Standard:Surgical excision pathology
Index test:HHUS,&#32
ABVS,&#32
and&#32

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. The patient was confirmed as invasive carcinoma by percutaneous needle biopsy (t1-3, n0-1, M0); 2. Aged >=18 years; 3. Patients who are NAT compliant, have no contraindications for chemotherapy and can receive NAC as planned; 4. Patients who underwent surgery after neoadjuvant chemotherapy and obtained pathological results; 5. Agree to participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with T4 breast cancer (ultrasound is not accurate enough to identify lesions outside the breast tissue, i.e. chest wall or skin); 2. Patients with a history of breast surgery or breast cancer chemoradiotherapy; 3. Patients who have not completed neoadjuvant chemotherapy; 4. Patients unable to receive CEUS or enhanced MRI scan; 5. For patients with distant metastasis, preoperative chemotherapy is rescue treatment, not neoadjuvant chemotherapy.

Design outcomes

Primary

MeasureTime frame
The value of shear wave speed;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactYi-feng Zhang

Shanghai Tenth People's Hospital

27763289@qq.com+86 13564843665

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026